LONDON--(BUSINESS WIRE)-- The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. Companies profiled include Abbott, AstraZeneca, Bayer, Eli Lilly, Johnson & Johnson, Novartis and Pfizer.
The market research report provides a detailed understanding and analysis of how and why companies enter vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
This market research report contains over 1,500 links to online copies of actual vaccine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Vaccine Partnering Terms and Agreements
Companies & Markets
London (UK): +44 (0) 203 086 8600
KEYWORDS: United Kingdom Europe
INDUSTRY KEYWORDS: Health Pharmaceutical